Medicine Recommendations

Constipation

 Moderate to severe irritable bowel syndrome with constipation

*FOR WEST LANCASHIRE ONLY* - Green for Second line option for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults

Constipation in adults

Constipation in children

Ulcerative colitis and Crohn's ONLY; only for inflammatory bowel diseases when patients are unable to tolerate azathioprine.

Ulcerative colitis

Crohn's Disease

Opioid induced bowel dysfunction in palliative care (NICE TA 277 terminated)

NICE is unable to recommend the use in the NHS because no evidence submission was received from the manufacturer of the technology

NICE TA277 - Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)

Moderately to severely active ulcerative colitis (NICE TA925)

NICE TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis

NICE TA651 -  For treating opioid-induced constipation

Opioid-induced constipation

Opioid-induced constipation (NICE TA345)

NICE TA 345 - Naloxegol for treating opioid‑induced constipation

Neurogenic bowel dysfunction

Non-neurogenic bowel dysfunction

Bowel obstruction - GI secretions associated with bowel obstruction. 

Bowel obstruction - nausea and vomiting associated with bowel obstruction

Treating moderately to severely active ulcerative colitis - NICE TA828

NICE TA828 - Ozanimod for treating moderately to severely active ulcerative colitis

Treatment of chronic constipation in women (NICE TA211) and Use in men: Prucalopride for the treatment of chronic constipation in men (LSCMMG recommendation)

NICE TA211 - Prucalopride for the treatment of chronic constipation in women

Treating moderately to severely active ulcerative colitis (NICE TA998)

NICE TA998 - Risankizumab for treating moderately to severely active ulcerative colitis

Previously treated moderately to severely active Crohn's disease (NICE TA888)

NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease